GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2

被引:100
|
作者
Biosa, Alice [1 ,2 ]
Trancikova, Alzbeta [1 ]
Civiero, Laura [3 ]
Glauser, Liliane [1 ]
Bubacco, Luigi [3 ]
Greggio, Elisa [3 ]
Moore, Darren J. [1 ]
机构
[1] Ecole Polytech Fed Lausanne, Brain Mind Inst, Sch Life Sci, CH-1015 Lausanne, Switzerland
[2] Univ Sassari, Sch Med, Dept Clin & Expt Med, I-07100 Sassari, Italy
[3] Univ Padua, Dept Biol, I-35121 Padua, Italy
基金
瑞士国家科学基金会;
关键词
ROC DOMAIN; GENE LRRK2; PROTEIN; MUTATIONS; BINDING; PHOSPHORYLATION; REVEALS; DIMER;
D O I
10.1093/hmg/dds522
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations in the LRRK2 gene cause autosomal dominant Parkinson's disease. LRRK2 encodes a multidomain protein containing a Ras-of-complex (Roc) GTPase domain, a C-terminal of Roc domain and a protein kinase domain. LRRK2 can function as a GTPase and protein kinase, although the interplay between these two enzymatic domains is poorly understood. Although guanine nucleotide binding is critically required for the kinase activity of LRRK2, the contribution of GTP hydrolysis is not known. In general, the molecular determinants regulating GTPase activity and how the GTPase domain contributes to the properties of LRRK2 remain to be clarified. Here, we identify a number of synthetic missense mutations in the GTPase domain that functionally modulate GTP binding and GTP hydrolysis and we employ these mutants to comprehensively explore the contribution of GTPase activity to the kinase activity and cellular phenotypes of LRRK2. Our data demonstrate that guanine nucleotide binding and, to a lesser extent, GTP hydrolysis are required for maintaining normal kinase activity and both activities contribute to the GTP-dependent activation of LRRK2 kinase activity. Guanine nucleotide binding but not GTP hydrolysis regulates the dimerization, structure and stability of LRRK2. Furthermore, GTP hydrolysis regulates the LRRK2-dependent inhibition of neurite outgrowth in primary cortical neurons but is unable to robustly modulate the effects of the familial G2019S mutation. Our study elucidates the role of GTPase activity in regulating kinase activity and cellular phenotypes of LRRK2 and has important implications for the validation of the GTPase domain as a molecular target for attenuating LRRK2-mediated neurodegeneration.
引用
收藏
页码:1140 / 1156
页数:17
相关论文
共 50 条
  • [1] GTPase Activity and Neuronal Toxicity of Parkinson's Disease-Associated LRRK2 Is Regulated by ArfGAP1
    Stafa, Klodjan
    Trancikova, Alzbeta
    Webber, Philip J.
    Glauser, Liliane
    West, Andrew B.
    Moore, Darren J.
    PLOS GENETICS, 2012, 8 (02):
  • [2] Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease
    Greggio, Elisa
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2012, 40 : 1058 - 1062
  • [3] GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2
    Blanca Ramirez, Marian
    Lara Ordonez, Antonio Jesus
    Fdez, Elena
    Madero-Perez, Jesus
    Gonnelli, Adriano
    Drouyer, Matthieu
    Chartier-Harlin, Marie-Christine
    Taymans, Jean-Marc
    Bubacco, Luigi
    Greggio, Elisa
    Hilfiker, Sabine
    HUMAN MOLECULAR GENETICS, 2017, 26 (14) : 2747 - 2767
  • [4] The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity
    Guo, Luxuan
    Gandhi, Payal N.
    Wang, Wen
    Petersen, Robert B.
    Wilson-Delfosse, Amy L.
    Chen, Shu G.
    EXPERIMENTAL CELL RESEARCH, 2007, 313 (16) : 3658 - 3670
  • [5] Rab29 activation of the Parkinson's disease-associated LRRK2 kinase
    Purlyte, Elena
    Dhekne, Herschel S.
    Sarhan, Adil R.
    Gomez, Rachel
    Lis, Pawel
    Wightman, Melanie
    Martinez, Terina N.
    Tonelli, Francesca
    Pfeffer, Suzanne R.
    Alessi, Dario R.
    EMBO JOURNAL, 2018, 37 (01) : 1 - 18
  • [6] LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease
    Xiong, Yulan
    Dawson, Valina L.
    Dawson, Ted M.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2012, 40 : 1074 - 1079
  • [7] Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease
    Gonzalez-Hunt, C. P.
    Thacker, E. A.
    Toste, C. M.
    Boularand, S.
    Deprets, S.
    Dubois, L.
    Sanders, L. H.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [8] Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2
    Singh, Ranjan K.
    Soliman, Ahmed
    Guaitoli, Giambattista
    Stoermer, Eliza
    von Zweydorf, Felix
    Dal Maso, Thomas
    Oun, Asmaa
    Van Rillaer, Laura
    Schmidt, Sven H.
    Chatterjee, Deep
    David, Joshua A.
    Pardon, Els
    Schwartz, Thomas U.
    Knapp, Stefan
    Kennedy, Eileen J.
    Steyaert, Jan
    Herberg, Friedrich W.
    Kortholt, Arjan
    Gloeckner, Christian Johannes
    Versees, Wim
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (09)
  • [9] Functional interaction of Parkinsons disease-associated LRRK2 with members of the dynamin GTPase superfamily
    Stafa, Klodjan
    Tsika, Elpida
    Moser, Roger
    Musso, Alessandra
    Glauser, Liliane
    Jones, Amy
    Biskup, Saskia
    Xiong, Yulan
    Bandopadhyay, Rina
    Dawson, Valina L.
    Dawson, Ted M.
    Moore, Darren J.
    HUMAN MOLECULAR GENETICS, 2014, 23 (08) : 2055 - 2077
  • [10] LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease
    Kedariti, Maria
    Frattini, Emanuele
    Baden, Pascale
    Cogo, Susanna
    Civiero, Laura
    Ziviani, Elena
    Zilio, Gianluca
    Bertoli, Federico
    Aureli, Massimo
    Kaganovich, Alice
    Cookson, Mark R.
    Stefanis, Leonidas
    Surface, Matthew
    Deleidi, Michela
    Di Fonzo, Alessio
    Alcalay, Roy N.
    Rideout, Hardy
    Greggio, Elisa
    Plotegher, Nicoletta
    NPJ PARKINSONS DISEASE, 2022, 8 (01)